Undeterred by barriers and challenges associated with lymphoma and the medical field, Dr. Sonali Smith’s work in the clinic and research realms, and natural-born leadership puts her at the forefront of advancing cures for this disease.
The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.
For Kami Maddocks, MD of the Ohio State University Comprehensive Cancer Center, the bonds she creates with her patients go far beyond the call of duty of a doctor and are the most rewarding aspect of her work.
LRF welcomes new SAB leadership and members Sonali M. Smith, MD of The University of Chicago (Chair); Ann S. LaCasce, MD, MMSc of Dana-Farber Cancer Institute (Chair-Elect); and Teresa Palomero, PhD of Columbia University (member)
The LRF Clinical Investigator Career Development Award (CDA) and Postdoctoral Fellowship Grant Program support junior faculty members and PhD and advanced clinical fellows pursuing research in lymphoma and chronic lymphocytic leukemia (CLL).
Dr. Christopher Flowers is passionate about working as a team and sharing with others the same enthusiasm for medicine that he has had since the onset of his career.
Lymphoma Research Foundation Funds 29 New Grants Investigating Lymphoma and Chronic Lymphocytic Leukemia, Introduces Expanded Research Program and Health Equity Initiative
Investment supports early-career scientists dedicated to developing patient therapies and lymphoma cures.
LRF Scientific Advisory Board (SAB) member and grantee Michael Williams, MD, of the University of Virginia School of Medicine, sees lymphoma research as having a ripple effect. A lymphoma researcher has a much larger impact on the lives of those touched by this disease.
Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provided a critical forum for leading hematologists/ oncologists to present their findings to over 20,000 of their peers.
Allogeneic hematopoietic stem cell transplant (allo-HSCT) may be a successful curative treatment for T-cell patients with poor survival and/or limited treatment options, according to a retrospective study led by LRF grantee Neha Mehta-Shah, MD of the Washington University School of Medicine in St. Louis.